Co-Diagnostics (NASDAQ:CODX) Inc, a molecular diagnostics company, has completed the principal design work on a PCR test for the monkeypox virus, the company announced.
Outbreaks of the virus have been reported in roughly 20 countries (primarily in Europe) where it is not endemic, with more than 200 confirmed or suspected infections, according to reporting from Reuters and others.
When complete, the new monkeypox test will feature the company's patented CoPrimer technology, and it was designed using its proprietary software system.
READ: Co-Diagnostics reports record 1Q revenue as company looks to expand into new markets and innovative molecular diagnostics solutions
"One of the most important lessons the world learned following the COVID-19 pandemic is the importance of quick, decisive action in the face of any potential outbreak of transmissible viruses," CEO Dwight Egan said in a statement. "This means being prepared for every scenario.”
He continued, “Co-Dx was founded with the mission to increase the accessibility of affordable, high-quality molecular testing products around the world, and we look forward to eventually making this test available in affected regions as needed to help slow the spread of the virus through early and accurate detection."
Based in Utah, Co-Diagnostics (NASDAQ:CODX) is a molecular diagnostics company that develops, manufactures, and markets new, state-of-the-art diagnostics technologies.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel